BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

246 related articles for article (PubMed ID: 25112227)

  • 1. Surgical treatment of prolactinomas: cons.
    Bloomgarden E; Molitch ME
    Endocrine; 2014 Dec; 47(3):730-3. PubMed ID: 25112227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Transsphenoidal Microsurgery for Prolactinomas - A Contemporary Series of 162 Cases.
    Giese S; Nasi-Kordhishti I; Honegger J
    Exp Clin Endocrinol Diabetes; 2021 Mar; 129(3):163-171. PubMed ID: 33461233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current Status of Surgery in Management of Prolactinomas.
    Panigrahi MK; Chandrasekhar YBVK; Vooturi S
    Neurol India; 2020; 68(Supplement):S39-S43. PubMed ID: 32611891
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SURGICAL OUTCOMES OF PROLACTINOMAS IN RECENT ERA: RESULTS OF A HETEROGENOUS GROUP.
    Donegan D; Atkinson JL; Jentoft M; Natt N; Nippoldt TB; Erickson B; Meyer F; Erickson D
    Endocr Pract; 2017 Jan; 23(1):37-45. PubMed ID: 27682355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current approach to treatments for prolactinomas.
    Tirosh A; Shimon I
    Minerva Endocrinol; 2016 Sep; 41(3):316-23. PubMed ID: 26399371
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Role of Surgery in the Management of Prolactinomas.
    Donoho DA; Laws ER
    Neurosurg Clin N Am; 2019 Oct; 30(4):509-514. PubMed ID: 31471058
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of hypophysectomy for prolactinomas in the era of dopamine agonist therapy.
    Soule SG; Farhi J; Conway GS; Jacobs HS; Powell M
    Clin Endocrinol (Oxf); 1996 Jun; 44(6):711-6. PubMed ID: 8759184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of resistant prolactinomas.
    Olafsdottir A; Schlechte J
    Nat Clin Pract Endocrinol Metab; 2006 Oct; 2(10):552-61. PubMed ID: 17024154
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical management of prolactin-secreting pituitary adenomas.
    Molitch ME
    Pituitary; 2002; 5(2):55-65. PubMed ID: 12675502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of Dopamine Agonist-Resistant Prolactinoma.
    Maiter D
    Neuroendocrinology; 2019; 109(1):42-50. PubMed ID: 30481756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical treatment of prolactinomas.
    Molitch ME
    Endocrinol Metab Clin North Am; 1999 Mar; 28(1):143-69, vii. PubMed ID: 10207689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risks of medical treatment of prolactinoma.
    Castinetti F; Albarel F; Amodru V; Cuny T; Dufour H; Graillon T; Morange I; Brue T
    Ann Endocrinol (Paris); 2021 Feb; 82(1):15-19. PubMed ID: 33373604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists.
    Hamilton DK; Vance ML; Boulos PT; Laws ER
    Pituitary; 2005; 8(1):53-60. PubMed ID: 16411069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current indications for the surgical treatment of prolactinomas.
    Smith TR; Hulou MM; Huang KT; Gokoglu A; Cote DJ; Woodmansee WW; Laws ER
    J Clin Neurosci; 2015 Nov; 22(11):1785-91. PubMed ID: 26277642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study.
    Wei L; Wei X
    Hormones (Athens); 2021 Dec; 20(4):745-752. PubMed ID: 34275094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Operative treatment of cystic prolactinomas: a retrospective study.
    Su W; He K; Yang Y; Xu J; Li X; Tang H; Yang J; Yang L
    BMC Endocr Disord; 2023 May; 23(1):99. PubMed ID: 37143054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of Prolactinoma.
    Inder WJ; Jang C
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Surgery for prolactinomas: a better choice?
    Honegger J; Nasi-Kordhishti I; Aboutaha N; Giese S
    Pituitary; 2020 Feb; 23(1):45-51. PubMed ID: 31853793
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Surgical Treatment of Prolactinomas: Potential Role as a First-Line Treatment Modality.
    Kim EH; Kim J; Ku CR; Lee EJ; Kim SH
    Yonsei Med J; 2023 Aug; 64(8):489-496. PubMed ID: 37488700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists.
    Park K; Park KH; Park HR; Lee JM; Kim YH; Kim DY; Won TB; Kong SH; Kim JH; Shin CS; Paek SH
    J Korean Med Sci; 2021 Apr; 36(15):e97. PubMed ID: 33876586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.